EADV24: Breakthrough in Early Melanoma Detection Using Tumour-Specific Antibodies

New research unveiled at the EADV Congress 2024 reveals a promising advancement in melanoma detection. This novel method utilises tumour-specific antibodies to identify early-stage melanoma, potentially revolutionising diagnosis and improving patient outcomes by detecting the disease at its most treatable stages.